Benzinga · Aug 10, 2026
Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $35
Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $27 to $35.
NASDAQ · BDSX
Biodesix, Inc.
Healthcare · Medical - Diagnostics & Research
$26.63
Down-$0.45 (-1.69%)
Updated Aug 24, 2026, 3:53 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 58.38M
- P/E ratio
- -1.5
- Dividend yield
- 0.00%
- 52-week range
- $9.43 – $27.11
- Volume
- 274.23K
- Avg. volume
- 160.55K
Price performance
BDSX price history
1M range · 20 trading sessions · Daily adjusted prices
BDSX closed at $26.63 after 20 trading sessions, up 19.85% for the selected period.
- Last close
- $26.63
- Period change
- +19.85%
- Period low
- $20.38
- Period high
- $26.63
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $24.25 | $27.105 | $24.11 | $26.63 | 274.23K |
| Aug 20, 2026 | $25.20 | $26.00 | $23.76 | $24.03 | 229.16K |
| Aug 19, 2026 | $21.91 | $26.3999 | $21.91 | $25.54 | 197.98K |
| Aug 18, 2026 | $23.03 | $23.03 | $22.00 | $22.34 | 106.76K |
| Aug 17, 2026 | $23.88 | $25.2697 | $22.7891 | $23.25 | 68.43K |
| Aug 14, 2026 | $23.88 | $24.43 | $23.585 | $24.00 | 72.43K |
| Aug 13, 2026 | $25.11 | $25.20 | $23.55 | $23.79 | 50.02K |
| Aug 12, 2026 | $24.62 | $25.40 | $23.80 | $24.22 | 91.66K |
| Aug 11, 2026 | $24.17 | $25.52 | $23.315 | $24.31 | 94.89K |
| Aug 10, 2026 | $24.09 | $25.51 | $23.37 | $24.86 | 160.93K |
| Aug 7, 2026 | $22.85 | $23.925 | $22.4501 | $23.50 | 81.13K |
| Aug 6, 2026 | $21.76 | $25.00 | $19.77 | $22.10 | 233.02K |
| Aug 5, 2026 | $22.89 | $23.40 | $22.41 | $22.78 | 43.09K |
| Aug 4, 2026 | $22.00 | $23.39 | $22.00 | $22.755 | 57.28K |
| Aug 3, 2026 | $21.52 | $23.38 | $21.52 | $22.03 | 86.24K |
| Jul 31, 2026 | $21.77 | $21.89 | $21.00 | $21.20 | 42.03K |
| Jul 30, 2026 | $20.715 | $22.00 | $20.70 | $21.335 | 44.78K |
| Jul 29, 2026 | $21.24 | $21.50 | $20.27 | $20.38 | 41.09K |
| Jul 28, 2026 | $22.27 | $22.3531 | $20.98 | $21.03 | 69.4K |
| Jul 27, 2026 | $22.13 | $23.384 | $21.78 | $22.22 | 75.47K |
Latest BDSX news
The latest Smart Investors Daily articles mentioning BDSX.
Stock researchCompany · Overview
BDSX research
Overview
Company profile and research snapshot.
Company profile
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $20.00
- Implied upside
- —
- Analysts
- 11
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Canaccord Genuity | Buy | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 25, 2026 | Roth Capital | Buy | — |
| Jun 18, 2026 | Canaccord Genuity | Buy | — |
| Jun 15, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 6, 2026
HC Wainwright & Co. Maintains Buy on Biodesix, Raises Price Target to $27
HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $26 to $27.
SeekingAlpha · Aug 6, 2026
Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript
Biodesix, Inc. (BDSX) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsScott Hutton - President, CEO & DirectorRobin Cowie - CFO,...
ChartMill · Aug 5, 2026
Biodesix (NASDAQ:BDSX) Q2 EPS Beats, Revenue In Line, Shares Slip
Biodesix Q2 revenue rises 34% to $26.9M, matching estimates; EPS loss beats forecasts. Shares fall 7% after hours as full-year guidance holds.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
